0001209191-17-042164.txt : 20170628
0001209191-17-042164.hdr.sgml : 20170628
20170628175057
ACCESSION NUMBER: 0001209191-17-042164
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170626
FILED AS OF DATE: 20170628
DATE AS OF CHANGE: 20170628
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: INGRAM DOUGLAS S
CENTRAL INDEX KEY: 0001190644
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 17936357
MAIL ADDRESS:
STREET 1: 2525 DUPONT DR
CITY: IRVINE
STATE: CA
ZIP: 92612
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-06-26
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001190644
INGRAM DOUGLAS S
215 FIRST STREET, SUITE 415
CAMBRIDGE
MA
02142
1
1
0
0
President & CEO
Common Stock
2017-06-26
4
A
0
335000
0.00
A
335000
D
Stock Option (right to buy)
34.65
2017-06-26
4
A
0
3300000
0.00
A
2027-06-26
Common Stock
3300000
3300000
D
Represents shares of restricted stock. Twenty-five percent of the shares will vest on June 26, 2018 and one thirty-sixth of the remaining unvested shares will vest on each monthly anniversary of June 26 thereafter, ending on June 26, 2021, in each case subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through each applicable vesting date.
On June 26, 2022, subject to the Reporting Person's continued service to the Issuer or a subsidiary thereof from the date of grant through such date, a percentage of the stock options will vest based on the extent to which the compounded annual growth rate ("CAGR") of the Issuer's stock price from June 26, 2017 (based on the closing price on such date) through June 26, 2022 (based on the average of the closing price of the Issuer's common stock on the 20 days immediately preceding such date) exceeds the CAGR of the NASDAQ Biotech Index (or any successor index) during the same period.
In certain situations, the stock options will expire within twelve months of such situation, but in no event will the stock options be exercisable after June 26, 2027.
/s/ David Tyronne Howton, as Attorney-in-Fact for Douglas S. Ingram
2017-06-28